In an uncommon move, the FDA has publicly weighed in on an in-development drug, clarifying the status of Sarepta Therapeutics’ closely watched Duchenne muscular dystrophy treatment eteplirsen in light of an earlier setback that tanked the biotech’s shares.

…read more

Source: FDA pulls back the curtain on Sarepta’s latest DMD delay


0 No comments